APX-NEW / AptaBio - LARVOL DELTA

Aptabio Therapeutics to present efficacy of Parkinson's disease treatment in US (Korea Biomedical Review) - "Aptabio Therapeutics...announced Monday that it will present preclinical results on the effectiveness of its treatment for Parkinson's disease, APX-NEW, in animal models at the Society of Neuroscience (SFN)....At SFN, Aptabio Therapeutics will present the study that explains the possibility of treating Parkinson's disease by reducing alpha-synuclein, a major contributor to the disease, through modulation of oxidative stress."

Preclinical • CNS Disorders • Parkinson's Disease

Aptabio publishes research results on Parkinson's disease treatment in international academic journal [Google translation] (HIT News) - "Aptabio...announced on the 7th that the results of non-clinical research on its Parkinson's disease treatment drug 'APX-NEW (development code name)' were published in the international journal 'International Journal of Molecular Sciences'....According to the research results, it was confirmed that APX-NEW was effective in treating Parkinson's disease in a dopaminergic cell (N27) and aged alpha-synuclein-preformed fibrils (PFF) induced Parkinson's disease model. According to the company, APX-NEW increased dopaminergic cell viability and reduced cytotoxicity at very low drug concentration (10nM), and reduced reactive oxygen species (ROS) and protein aggregation (Thyflavine-T staining) in cells."

Preclinical • CNS Disorders • Parkinson's Disease

AptaBio to present oxidative stress as method for treating Parkinson's disease (Korea Biomedical Review) - "AptaBio...said on Tuesday that it will present the treatment effect of APX-NEW, an oxidative stress drug for the treatment of Parkinson's disease, at the Society for Neuroscience (SFN) on Nov.12-16 in San Diego, the U.S....According to AptaBio, APX-NEW demonstrated that it is possible to effectively improve dopamine nerve loss and motor impairment by reducing the accumulation and protein aggregation of alpha-synuclein....Through an animal model using alpha-synuclein-preformed fibrils (PFF), AptaBio confirmed the treatment effects of APX-NEW and that NOX protein plays a very pivotal role in the abnormal accumulation of alpha-synuclein and the development of Parkinson's disease....Accordingly, it was shown that when APX-NEW (Comp-11) was applied, the expression of NOX 1, 2, and 4 proteins in the brain tissue was inhibited, and alpha-synuclein was also reduced in a concentration-dependent manner."

Preclinical • CNS Disorders • Parkinson's Disease

Aptabio Parkinson's disease drug candidate confirmed efficacy in animal testing [Google translation] (Health Korea News) - "Aptabio...announced on the 19th that its brain disease treatment substance 'APX-NEW'...was tested in a non-clinical trial (animal model) confirmed that the Parkinson's disease treatment effect was excellent. A paper containing the research results (A Novel NOX Inhibitor Treatment Attenuates Parkinson's Disease-Related Pathology in Mouse Models) was published in the latest issue of 'International Journal of Molecular Sciences'....In this paper, Aptabio claimed that 'APX-NEW derived from the NOX platform derived significant results in an animal model of Parkinson's disease. It was confirmed that alpha-synuclein accumulation and protein aggregation were reduced through oxidative stress (ROS) inhibition in neurons and animal models of Parkinson's disease, thereby improving dopaminergic nerve loss and movement disorders."

Preclinical

Aptabio Parkinson's disease drug candidate confirmed efficacy in animal testing (Health Korea News) - "Aptabio...announced on the 19th that its brain disease treatment substance 'APX-NEW'...was tested in a non-clinical trial (animal model) confirmed that the Parkinson's disease treatment effect was excellent. A paper containing the research results (A Novel NOX Inhibitor Treatment Attenuates Parkinson's Disease-Related Pathology in Mouse Models) was published in the latest issue of 'International Journal of Molecular Sciences', a specialized academic journal in the field of biochemistry....It was confirmed that alpha-synuclein accumulation and protein aggregation were reduced through oxidative stress (ROS) inhibition in neurons and animal models of Parkinson's disease, thereby improving dopaminergic nerve loss and movement disorders."

Preclinical • CNS Disorders • Parkinson's Disease